Track topics on Twitter Track topics that are important to you
Celladon Corporation, based in La Jolla, California, was launched in October 2004 as a privately held biotechnology company founded with the goal of becoming the leader in developing molecular therapies for the treatment of heart failure. The companyâs products target the key enzyme deficiency in advanced heart failure, SERCA2a, which regulates calcium cycling and contractility in heart muscle cells. Celladonâs first product candidate, MYDICARÂ®, delivers the gene for the SERCA2a enzyme and is currently being tested in Phase 1 and 2 clinical trials. Celladon is also developing traditional small molecule activators of SERCA2a for the treatment of heart failure. To learn more about Celladon, visit Celladonâs website at www.celladon.net.
2223 Avenida de la Playa #206
United States of America
TORONTO, ONTARIO -- (Marketwired) -- 02/14/17 -- As a result of an agreement effective February 13, 2017 in relation to the conversion of certain outstanding debt of The Jenex Corporation (the "Corp...
Oriola-KD Corporation Stock Exchange Release 4 January 2017 at 9.00 a.m. Oriola-KD Corporation's 50,375 A-shares converted into B-shares In accordance with Section 3 of the Byla...
Oriola-KD Corporation Stock Exchange Release 7 October 2016 at 2.00 p.m. Oriola-KD Corporation will publish the interim report 1 January - 30 September 2016 on Thursday, 20 October 201...
Oriola-KD Corporation Stock Exchange Release 24 November 2016 at 1.00 p.m. Publication schedule for Oriola-KD Corporation's financial reporting in 2017 Oriola-KD Corporation will...
Oriola-KD Corporation Stock Exchange Release 25 January 2017 at 1.00 p.m. Oriola-KD Corporation will publish its financial statements release 1 January-31 December 2016 on Monday, 13 ...
This is a correction of the announcement from 14:00 07.10.2016 EEST. Reason for the correction: There was an error considering the meeting schedule for investors, analysts and the pre...
Oriola-KD Corporation Stock Exchange Release 4 November 2016 at 12.00 Oriola-KD Corporation: Notification of managers' transactions ...
ORION CORPORATION STOCK EXCHANGE RELEASE 27 JANUARY 2017 at 9.10 a.m. EET 193,881 Orion Corporation A shares converted into B shares In acco...
Celladon Corp., based in La Jolla, Calif., was launched in October 2004 as a privately held biotechnology company with the goal of becoming the leader in developing molecular therapies for the treatme...
Celladon Corporation, based in La Jolla, California, was launched in October 2004 as a privately held biotechnology company founded with the goal of becoming the leader in develop...
Toshiba Medical Systems Corporation is a leading worldwide provider of medical diagnostic imaging systems and comprehensive medical solutions, such as CT, X-ray and vascular, ultr...
Bruker Corporation is a leading provider of high-performance scientific instruments and solutions for molecular and materials research, as well as for industrial and applied analy...
Hot Spring Spas is the worldâs leading brand of hot tubs and is sold through a network of more than 700 independent dealers throughout North America and 70 countries around t...
We have published hundreds of Celladon Corporation news stories on BioPortfolio along with dozens of Celladon Corporation Clinical Trials and PubMed Articles about Celladon Corporation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Celladon Corporation Companies in our database. You can also find out about relevant Celladon Corporation Drugs and Medications on this site too.
Antibodies Antisense Assays Biochips Bioinformatics Biological Therapy Biomarkers Biomaterials Bioscience Cell Culture Cloning Cytokine Diagnostics Dna Extraction Dna Sequencing Dna Transform...
Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...